Abstract. New-onset diabetes after renal transplantation (NODAT) is known to be a potent risk factor for cardiovascular events. We therefore investigated the incidence and risk factors for NODAT, and evaluated surrogate endpoints of atherosclerosis in Japanese patients with stable renal function after renal transplantation. Seventy-nine patients were enrolled in the study, and a 75 g oral glucose tolerance test (OGTT) was performed in subjects excluding patients with known NODAT. We evaluated the risk factors for NODAT and the degree of atherosclerosis, determined by brachialankle pulse wave velocity (baPWV), ankle-brachial blood pressure index (ABPI) and intima-media thickness (IMT) of the carotid artery. Eleven patients diagnosed as NODAT had significantly higher fasting plasma glucose before transplantation, blood pressure, and incidence of hepatitis C virus (HCV) infection than patients without NODAT. Multivariate regression analysis revealed that the independent determinant of NODAT was fasting plasma glucose pretransplantation, HCV infection and systolic blood pressure. The baPWV in patients with NODAT was significantly higher compared to that in patients without NODAT. In addition, the independent determinant of baPWV evaluated by multivariate regression analysis was an increase in systolic blood pressure and age, and a decrease of adiponectin levels.
SHORT-TERM renal allograft survival was dramatically enhanced with the improvement of immunosuppressive therapy, while long-term allograft survival remains problematic. Major complications of longterm allograft survival include cardiovascular disease as well as chronic allograft failure. Acute coronary syndrome is highly prevalent during the early posttransplant period and on average, cardiovascular disease mortality accounts for 30% and 75% of early and late post-transplant deaths, respectively [1] [2] [3] . Various risk factors for cardiovascular disease have been identified in renal transplant recipients, such as dyslipidemia, hypertension, hyperglycemia, smoking, renal allograft dysfunction, anemia, and an increase in inflammatory cytokines [4, 5] . Furthermore, new-onset diabetes after transplantation (NODAT) has recently been established as a potent risk factor for cardiovas-cular disease in addition to diabetes prior to dialysis [6] [7] [8] . The incidence of cardiovascular disease was approximately three times higher in renal transplant recipients with NODAT than those without NODAT [9] . It is therefore very important to evaluate the degree of glucose tolerance and atherosclerosis of renal transplant recipients to improve allograft survival and mortality after renal transplantation.
Pulse wave velocity (PWV), ankle-brachial blood pressure index (ABPI) and intima-media thickness (IMT) of the carotid artery are accepted as strong independent predictors for cardiovascular events and mortality [10] [11] [12] . Recently, an instrument for measuring ABPI and brachial-ankle PWV (baPWV) by a volumerendering method was developed [13] . These measurements are widely used to evaluate the degree of atherosclerosis, because the methods are easy, noninvasive and repeatable. A number of studies revealed that these surrogate endpoints were worsened in patients with end-stage renal failure [14, 15] , and that renal transplantation could partially improve increased arterial stiffness [16] . However, it has not been fully evaluated whether NODAT affects these surrogate endpoints.
We therefore determined the impact of NODAT on baPWV, ABPI and IMT and the relationship between various risk factors and arterial function in renal transplant recipients in a single center cross sectional study.
Materials and Methods
Seventy-nine patients with renal transplants performed from 1998 to 2005 at Osaka University Medical Hospital were enrolled in this study. These subjects were stable renal transplant recipients without pre-existing diabetes. We excluded patients who had a plasma glucose concentration of greater than 7.0 mmol/L at the fasting state or 11 mmol/L 2 hours after a 75 g oral glucose load prior to transplantation. Immediately after transplantation, patients received immunosuppressant treatment composed either of antilymphocyte globulin or basiliximab with corticosteroids. The immunosuppressant treatment was based on calcineurin inhibitors (48 mg/day of tacrolimus and 31 mg/day of cyclosporine) with prednisolone and mycophenolate mofetile after the renal function was stabilized.
The study was approved by the Ethical Committee for Human Studies at Osaka University Hospital. After giving a detailed explanation of the study using a document, written informed consent was obtained from each subject. The oral glucose tolerance test (OGTT) was performed on all subjects excluding patients with known NODAT who had insulin therapy post-transplantation upon enrollment in the study. Plasma glucose and serum insulin levels were measured at 0, 30, 60 and 120 min after commencement of the OGTT. Diagnosis of NODAT has been clarified by the International Consensus Guidelines, which recommends diagnostic criteria for NODAT to mirror that of type 1 and type 2 diabetes mellitus as based on the American Diabetes Association and World Health Organization guidelines [17] [18] [19] . The degree of insulin resistance and insulin secretion was evaluated as the homeostasis model assessment of insulin resistance (HOMA-IR) and insulinogenic index, respectively. We also measured serum creatinine, adiponectin, lipid profile and high sensitive C-reactive protein (hsCRP) levels in the fasting state on the day of the OGTT. HCV and CMV infections were determined at pretransplantation [9, 20] . The baPWV and ABPI were determined by using a device (AT-form PWV/ABI; Nippon Colin, Komaki, Japan) that can simultaneously monitor bilateral brachial and ankle pressure wave forms by the volume plethysmographic method, with optional tonometry sensors for carotid arterial wave measurements. To evaluate baPWV, the time duration between the brachial wave form and ankle wave form was automatically calculated as the heart-ankle time duration minus the heart-brachial time duration. The ABPI was calculated by the ankle systolic pressure divided by the arm systolic pressure. To evaluate the IMT, ultrasonographic scanning of the carotid artery was performed using an echotomographic system (Aplio SSA-700A; Toshiba Medical Systems Corp., Japan) with an electrical linear transducer (midfrequency 7.5 MHz). Scanning of the extracranial common carotid artery, the carotid bulb, and the internal carotid artery in the neck was performed bilaterally from three different longitudinal projections (i.e., anterior oblique, lateral, and posterior oblique) as well as the transverse projections, as reported in our previous studies [21] [22] [23] . All of the images were photocopied. The detection limit of this echo system using 7.5 MHz was 0.1 mm. The IMT was measured as the distance from the leading edge of the first echogenic line to the leading edge of the second echogenic line [24] . The first line represents the lumen-intima interface, and the second line is produced by the collagen-containing upper layer of the tunica adventitia. At each longitudinal projection, the site of the greatest thickness including a plaque lesion was sought along the arterial walls. Three determinations of IMT, one at the site of the thickest point, maximum IMT (Max-IMT), and two at adjacent points (located 1 cm upstream and 1 cm downstream from this site) were conducted. These three determinations were averaged (Mean-IMT). Higher values of IMT and baPWV, and the lower value of ABPI between both sides were used as representative values of the individuals for analysis.
Data are represented as means ± SD. Statistical comparisons between the patients with and without NODAT were assessed using ANOVA. The χ 2 test for trend was used to determine the relationship between the incidence of NODAT and risk factors such as HCV infection, family history of diabetes, and immunosuppressive treatments. Multivariate logistic regression analysis was performed to estimate the factors independently correlating with NODAT. Multivariate regression analyses were performed to evaluate the relationship between surrogate markers of cardiovascular disease and various risk factors for atherosclerosis. For multivariate regression analyses, the F value for the inclusion and exclusion of variables was set at 2.0. A p value of less than 0.05 was considered statistically significant. Analyses were performed with HALBAU statistical software (Gendai Sugaku-sha, Kyoto, Japan) on a personal computer. The threshold of statistical significance was defined as p<0.05.
Results
A total of 79 renal stable transplant recipients consented to the study and 77 subjects excluding patients with known NODAT underwent the OGTT. Clinical characteristics and metabolic parameters of the renal transplant recipients used in this study were as follows: 44 men and 35 women, age 44.6 ± 11.9 years, duration after transplantation 39.9 ± 23.2 months, body mass index (BMI) 21.2 ± 3.8, serum creatinine levels 124.7 ± 37.7 μmol/L, glycated hemoglobin A 1C (HbA 1C ) 5.2 ± 0.6%, and fasting plasma glucose (FPG) 4.8 ± 0.9 mmol/L at the time of enrollment in the study. Prior to transplantation, BMI (20.7 ± 3.2) and FPG (4.8 ± 0.5 mmol/L) values were similar to those at the time of enrollment, although the HbA 1C (4.6 ± 0.5%) level was significantly lower than that at the time of enrollment.
Eleven patients were diagnosed as NODAT, and 7 and 61 patients (Non-NODAT) were diagnosed to have impaired glucose tolerance and normal glucose tolerance, respectively. In NODAT patients, plasma glucose levels during the OGTT and HOMA-IR were significantly higher than those of Non-NODAT subjects, while the insulinogenic index was significantly lower than that in Non-NODAT subjects (Table 1) . Patients with NODAT had a significantly higher age at transplantation, fasting plasma glucose concentration prior to transplantation, systolic blood pressure and low-density lipoprotein cholesterol (LDL-C) upon the OGTT compared with Non-NODAT subjects (Table  2) . Among the other previously reported risk factors for NODAT, such as infection of HCV and CMV, family history of diabetes, class of calcineurin inhibitors, and treatment with high dose prednisolone at episodes of acute rejection, only the incidence of HCV infection was significantly higher in NODAT patients compared with Non-NODAT subjects. Multivariate logistic regression analysis revealed that the risk factors for NODAT were the incidence of HCV, high fasting plasma glucose levels prior to transplantation, and high systolic blood pressure (Table 3) at the time of enrollment. Data are given as means ± S.D. Data between the groups were compared by the one-way ANOVA followed by Scheffe's test.
NS: not significant
Furthermore, we assessed the surrogate endpoints for cardiovascular disease in NODAT and Non-NODAT subjects. As shown in Table 2 , the baPWV in NODAT patients was significantly higher than that in Non-NODAT subjects, while there were no significant differences in Max-IMT, Mean-IMT and ABPI between the two groups. The baPWV was positively correlated with HbA 1C , age, systolic blood pressure, and Max-IMT levels, and negatively correlated with adiponectin levels. Multivariate regression analyses revealed that high blood pressure, age, and low adiponectin levels were independent determinants for developing arterial stiffness (Table 4) . Multivariate logistic regression analysis was performed for 79 subjects with stable renal function after renal transplantation to select variables significantly associated with NODAT. Variables were considered for the multivariable models when their univariable p-value was less than 0.05. CI: confidential interval
Discussion
In the present study, we firstly demonstrated that new-onset diabetes after renal transplantation induces arterial wall stiffening as determined by baPWV. Arterial stiffness is known to increase before dialysis in patients with chronic renal disease [14, 15] , and renal transplantation improves this increased arterial stiffness [16] . In addition, hyperglycemia itself is known to be a potent promoter for developing arterial stiffness in patients with type 1 and type 2 diabetes [25, 26] . In this study, since the average baPWV level was within the normal range in the renal transplant recipients without NODAT, renal transplantation may have improved their arterial stiffness. Multivariate regression analyses demonstrated that the independent risk factors for arterial stiffening were an increase in blood pressure and age, and a decrease in adiponectin levels, but not an increase in hemoglobin A 1C levels, in all renal transplant patients. Since hypertension was a risk factor for NODAT, increased blood pressure, but not hyperglycemia, could be a major cause of arterial stiffness in NODAT. Hypertension is also known to be the most potent factor for developing arterial stiffness in end-stage renal disease [27] . Therefore, strict control of hypertension may be a key factor in preventing NODAT and atherosclerosis after renal transplantation. The HbA 1C level of 8 out of 11 patients with NODAT was within the normal range (less than 5.8%), and thus such mild hyperglycemia failed to contribute to increased arterial stiffness.
A previous report in patients with hypertension demonstrated that low serum adiponectin levels, as well as high arterial pressure and age, were independently related to arterial stiffness [28] . In the present study, we found a similar correlation between high baPWV and low serum adiponectin levels in renal transplant patients. Adiponectin is known to correlate directly with whole-body insulin sensitivity, which is a major cause of diabetes [29] and cardiovascular disease [30] . In the present study, however, plasma adiponectin levels were not correlated with the index of insulin resistance, HOMA-IR. Thus the effect of adiponectin on preventing arterial stiffness may be independent of the effect of insulin resistance after renal transplantation. In addition, the absolute levels of serum adiponectin in the subjects of the present study were elevated compared with those of Japanese subjects with various types of glucose tolerance in our previous report [31] . Several reports demonstrated similar findings that adiponectin levels were increased in subjects with end-stage renal disease and after renal transplantation [32] . Our results suggest that a lower adiponectin level may contribute to the development of atherosclerosis in renal transplant recipients.
We found that patients with NODAT have a higher HOMA-IR and lower insulinogenic index, indicating that the pathogenesis of NODAT involves an impairment of both insulin action and insulin secretory ability. Since the dosage and class of immunosuppressants used were identical between the patients with and without NODAT, impaired insulin secretion and ac- Since plasma glucose levels prior to transplantation were significantly higher in patients with NODAT, evaluation of glucose tolerance by the OGTT may be beneficial for predicting the development of NODAT prior to transplantation. We should therefore treat renal transplant recipients that have fasting hyperglycemia or impaired glucose tolerance with strict intervention of their lifestyle prior to transplantation. In addition to immunosuppressive drugs and previous glucose intolerance, age, race, and family history of diabetes were reported as non-modifiable risk factors for developing NODAT, whereas obesity, HCV and CMV infections [33, 34] were reported as modifiable risk factors. In this study, we found that HCV infection prior to transplantation was a risk factor for NODAT in renal transplant recipients. HCV infection is a well known risk factor for not only NODAT, but also type 2 diabetes, probably due to impaired insulin action in the liver [35] . In addition to these risk factors, lower adiponectin and higher high sensitive Creactive protein (hs-CRP) levels were recently reported to be associated with NODAT [36] , but we failed to observe such correlations.
In conclusion, we found that high fasting plasma glucose prior to transplantation, HCV infection and high blood pressure are risk factors for new-onset diabetes in Japanese patients after renal transplantation. Development of diabetes after transplantation induces increased arterial stiffness probably due to elevated blood pressure. Strict treatment for hypertension and mild fasting hyperglycemia will therefore be beneficial for the prevention of new-onset diabetes and cardiovascular disease after renal transplantation.
